Who is sponsoring NCT03131362?

NCT03131362 is sponsored by AstraZeneca.

What condition does NCT03131362 study?

NCT03131362 studies Chronic Obstructive Pulmonary Disease COPD.

Is NCT03131362 still recruiting?

NCT03131362 is currently completed. Last updated 26 January 2022.

Last reviewed 2022-01-26 · How we verify

NCT03131362: REAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Realize the Current Situation of COPD Patients in China

Completed Last updated 26 January 2022

What this trial tests

trial in Chronic Obstructive Pulmonary Disease COPD in 5,020 participants. Completed in 6 August 2020.

Timeline

30 June 2017

Primary endpoint
6 August 2020

6 August 2020

Quick facts

Lead sponsor	AstraZeneca
Status	Completed
Study type	OBSERVATIONAL
Enrollment	5,020
Start date	30 June 2017
Primary completion	6 August 2020
Estimated completion	6 August 2020
Sites	1 location across China

Conditions studied

Chronic Obstructive Pulmonary Disease COPD — all drugs for Chronic Obstructive Pulmonary Disease COPD →

Sponsor

AstraZeneca — full company profile →

Who can join

Eligibility, any sex, with Chronic Obstructive Pulmonary Disease COPD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-centre, prospective, observational study to realize the current situation of COPD patients in China. About 5000 COPD patients will be enrolled from 50 participating sites around China and followed up for one year. During this study, patients will undergo clinical assessments and receive medical care as determined by their treating physician.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Severity distribution and treatment of chronic obstructive pulmonary disease in China: baseline results of an observational study.
Yang T, Cai B, Cao B, Kang J, et al · · 2022 · cited 19× · PMID 35488337 · DOI 10.1186/s12931-022-02021-w
REALizing and improving management of stable COPD in China: a multi-center, prospective, observational study to realize the current situation of COPD patients in China (REAL) - rationale, study design, and protocol.
Yang T, Cai B, Cao B, Kang J, et al · · 2020 · cited 10× · PMID 31931767 · DOI 10.1186/s12890-019-1000-x
Exacerbation in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL).
Yang T, Cai B, Cao B, Kang J, et al · · 2023 · cited 7× · PMID 37073797 · DOI 10.1177/17534666231167353
Treatment patterns in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL).
Yang T, Cai B, Cao B, Kang J, et al · · 2023 · cited 7× · PMID 37013442 · DOI 10.1177/17534666231158283
REALizing and improving management of stable COPD in China: results of a multicentre, prospective, observational study (REAL).
Yang T, Cai B, Cao B, Kang J, et al · · 2023 · cited 5× · PMID 37318116 · DOI 10.1177/17534666231178692
REALizing and improving management of stable COPD in China: Results of a multicentre, prospective, observational study (REAL)
Yang T, Cai B, Cao B, Kang J, et al · · 2022 · DOI 10.21203/rs.3.rs-1457547/v1
Severity Distribution and Treatment of Chronic Obstructive Pulmonary Disease in China: Baseline Results of an Observational Study
Yang T, Cai B, Cao B, Kang J, et al · · 2021 · DOI 10.21203/rs.3.rs-346762/v1

Verify or expand the search:

Other recruiting trials for Chronic Obstructive Pulmonary Disease COPD

Currently open trials in the same condition.

NCT07380711 — Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported Outcomes · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03131362 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 26 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03131362.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing